Kristina Jankovic/X
Jan 20, 2025, 13:56
Kristina Jankovic: FDA approved datopotamab, deruxtecan-dlnk for unresectable, metastatic, HR+ HER2- breast cancer
Kristina Jankovic, Medical Oncology Resident at University Clinical Center Nis, shared a post on X:
“DC Approval!! US FDA approved datopotamab, deruxtecan-dlnk for unresectable, metastatic, HR+ HER2- Breast Cancer previously treated with endocrine and chemotherapy for unresectable, metastatic disease. ”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 25, 2025, 16:56
Feb 25, 2025, 15:10
Feb 25, 2025, 14:12
Feb 25, 2025, 14:04
Feb 25, 2025, 13:56
Feb 25, 2025, 13:46
Feb 25, 2025, 13:38